Reni Benjamin
Stock Analyst at JMP Securities
(1.26)
# 3,544
Out of 4,944 analysts
173
Total ratings
36.17%
Success rate
-18.73%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.05 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $22.04 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $7.87 | +179.54% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.80 | +150.00% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.37 | +171.22% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $83.31 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.66 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.21 | +230.58% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.49 | +168.46% | 1 | Aug 8, 2022 | |
| ADVM Adverum Biotechnologies | Upgrades: Market Perform | n/a | $2.53 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.13 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.45 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.08 | +20,025.79% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $16.77 | -40.37% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $3.18 | +57.23% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $6.53 | +328.79% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $27.03 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $26.70 | +49.81% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.53 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.38 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.83 | +382.51% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.78 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $8.62 | -7.14% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $49.70 | +20.72% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $8.40 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $214.85 | +46.61% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $91.36 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $244.89 | +8.21% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.56 | +378.20% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.34 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $8.79 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.56 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $27.47 | -56.32% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.29 | - | 1 | Nov 15, 2017 |
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.05
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $22.04
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $7.87
Upside: +179.54%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.80
Upside: +150.00%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.37
Upside: +171.22%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $83.31
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.66
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.21
Upside: +230.58%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.49
Upside: +168.46%
Adverum Biotechnologies
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $2.53
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.13
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $7.45
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.08
Upside: +20,025.79%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $16.77
Upside: -40.37%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $3.18
Upside: +57.23%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $6.53
Upside: +328.79%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $27.03
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $26.70
Upside: +49.81%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.53
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.38
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.83
Upside: +382.51%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.78
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $8.62
Upside: -7.14%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $49.70
Upside: +20.72%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $8.40
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $214.85
Upside: +46.61%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $91.36
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $244.89
Upside: +8.21%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.56
Upside: +378.20%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.34
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $8.79
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.56
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $27.47
Upside: -56.32%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $19.29
Upside: -